Keystone is our proprietary analytics platform for microbiome analysis with applications in areas such as clinical trial analysis and early disease prediction. Supported by a state-of-the-art cloud-based IT infrastructure, Keystone is able to operate in any region globally and process high throughput data analysis. We employ a range of innovative statistical bioinformatics methodology, machine learning and data visualization tools for large-scale data analysis and interpretation. Keystone brings quality, precision, and new insights to drug development.

Some Keystone analytic outputs include:

The Microbiome Artificial Intelligence Drug ENabler (MAIDEN) takes advantage of a large database of disease biology and microbiome datasets to discovery small molecule therapeutics. MAIDEN integrates computational biology and chemistry to increase precision in drug candidate identification. Currently, approximately 50% of approved drugs utilised natural products as the genesis for the development of new therapeutics. Novel structural scaffolds/motifs harnessed from bioactive natural products facilitate the discovery of new molecules with high biological relevance. MAIDEN works with the promising field of microbiome yet delivers to Pharma with an actionable drug modality that complements the existing drug development and regulatory frameworks.